Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10918973 | Radiotherapy and Oncology | 2011 | 8 Pages |
Abstract
The dose distribution that is actually delivered to patients significantly differs from what was planned because of anatomic modifications. Adaptive multi-modality IMRT is feasible in H&N tumors and could compensate and improve dose distribution. Some useful surrogate criteria or “flags” are, however, needed to identify patients who might benefit from an adaptive strategy. The optimal adaptive strategy still needs to be defined and prospective studies will have to be conducted to address the safety and the clinical impact of such approaches on patient outcome.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Pierre Castadot, Xavier Geets, John Aldo Lee, Vincent Grégoire,